PDL BioPharma (PDLI) - Investing in Evofem

09:30 EDT 16 Apr 2019 | Edison Investment Research

Edison Investment Research - Pharmaceuticals & healthcare - PDL BioPharma: PDL announced that it will invest a total of up to $60m in two tranches of $30m each in Evofem, a women’s health company that is preparing to submit an NDA for Amphora, a non-hormonal female contraceptive, in H219 with a launch expected in 2020. In December, Evofem announced that it achieved the primary endpoint in the 1,400-patient AMPOWER trial with a seven-cycle cumulative pregnancy probability of 14% with the upper limit of the confidence interval at 18%. The pre-specified hurdle in the trial, as agreed to by the FDA, was a seven-cycle pregnancy rate of 16.5% with an upper limit of the confidence interval at 21%.
ISIN: US69329Y1047

Original Article: PDL BioPharma (PDLI) - Investing in Evofem


More From BioPortfolio on "PDL BioPharma (PDLI) - Investing in Evofem"

Quick Search


Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...